No article text was recorded for this version.
treatment burden
Version 1 of 116 papers17 conceptsfrozen 2026-10-04
Papers in this version
- Blog: Study on the efficacy of different injection regimens of aflibercept in the treatment of diabetic macular edema
- Blog: High-Dose 8 mg Aflibercept for Neovascular Age-Related Macular Degeneration: Who Is Being Treated with This New Agent?
- Blog: Efficacy of switching treatment to faricimab in recalcitrant neovascular age related macular degeneration – 6 month results after completion of the loading phase
- Blog: Safety and Efficacy of Multiple Escalating Doses of RC28-E for Neovascular Age-Related Macular Degeneration: A Phase 1b Trial
- Blog: Ghrelin Ameliorates Diabetic Retinal Injury: Potential Therapeutic Avenues for Diabetic Retinopathy
- Blog: Efbemalenograstim Alfa, an Fc Fusion Protein, Long‑Acting Granulocyte Colony-Stimulating Factor for Reducing the Risk of Chemotherapy-Induced Neutropenia: Results of a Phase II Randomized, Multicenter, Open‑Label Trial
- Blog: Romiplostim versus Recombinant human thrombopoietin in umbilical cord blood transplantation: a single-center retrospective study
- Blog: Extended Real-World Efficacy of Faricimab in Therapy-Resistant Macular Edema Due to Retinal Vein Occlusion: 9-Month Follow-Up Results
- Blog: Deep learning-assisted analysis of biomarker changes after increase of dosing from aflibercept 2 mg to 8 mg in therapy-resistant neovascular age-related macular degeneration
- Blog: A 6-month sustained-release formulation of triptorelin for locally advanced or metastatic prostate cancer: a real-world experience in Asia
- Blog: Intravitreal ranibizumab injection combined with photodynamic therapy for polypoidal choroidal vasculopathy
- Blog: Nanotechnology for Age-Related Macular Degeneration
- Blog: Intravitreal aflibercept 8 mg in patients from Japan with diabetic macular edema: 48-week subgroup analysis of the PHOTON trial
- Blog: Combination pharmacotherapy for macular edema associated with retinal vein occlusion
- Blog: Nme<sub>2</sub>Cas9‐mediated therapeutic editing in inhibiting angiogenesis after wet age‐related macular degeneration onset
- Blog: Retinal and choroidal efficacy of switching treatment to faricimab in recalcitrant neovascular age related macular degeneration
History & citation
Current · Permanent link
Cite this direction
Latest version (a living page):
@misc{lacuna_treatment_burden_12071487,
title = {treatment burden},
author = {{Lacuna}},
howpublished = {Lacuna research direction},
year = {2026},
url = {https://lacuna.tiptreesystems.com/direction/treatment-burden/rdr_120714879a9c463ea4e3f53b8ce62a99},
note = {Latest version of a living research direction; cite a version for a fixed text. Accessed 2026-11-20},
}This exact version (version 1, frozen text):
@misc{lacuna_treatment_burden_12071487_v1,
title = {treatment burden},
author = {{Lacuna}},
howpublished = {Lacuna research direction},
year = {2026},
url = {https://lacuna.tiptreesystems.com/direction/treatment-burden/rdr_120714879a9c463ea4e3f53b8ce62a99/v/1},
note = {Version 1, frozen 2026-10-04. Accessed 2026-11-20},
}